Skip to contentG
Grace Therapeutics, Inc.
G
GRCEGrace Therapeutics, Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$3.89M-$3.89MN/M vs Q3 2022 EPS Diluted-$0.09-$0.09N/M vs Q3 2022 Operating Income-$4,245,000N/M Operating Cash Flowderived-$3,722,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Feb 14, 2023 · 45 d after period end